Company news
Evommune, Inc. (NYSE:EVMN) news
Evommune, Inc. news releases on 6ix. Latest, Oct 1, 2026: Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic…
Press releases & updates
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
October 1, 2026
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
September 23, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
September 8, 2026
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 6, 2026
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
July 30, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
June 29, 2026
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 7, 2026
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
April 6, 2026
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 5, 2026
Evommune Announces $125 Million Private Placement
February 12, 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
February 10, 2026
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
December 11, 2025
Evommune Announces Pricing of its Initial Public Offering
November 4, 2025
Evommune Announces Commencement of Initial Public Offering
October 30, 2025